447 related articles for article (PubMed ID: 28617319)
1. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Spadaccini M; D'Alessio S; Peyrin-Biroulet L; Danese S
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617319
[TBL] [Abstract][Full Text] [Related]
2. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
[TBL] [Abstract][Full Text] [Related]
4. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
[TBL] [Abstract][Full Text] [Related]
5. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
8. Apremilast in the treatment of psoriasis and psoriatic arthritis.
Gooderham M; Papp K
Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
10. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Li H; Fan C; Feng C; Wu Y; Lu H; He P; Yang X; Zhu F; Qi Q; Gao Y; Zuo J; Tang W
Br J Pharmacol; 2019 Jul; 176(13):2209-2226. PubMed ID: 30883697
[TBL] [Abstract][Full Text] [Related]
12. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Sakkas LI; Mavropoulos A; Bogdanos DP
Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
15. Apremilast in psoriatic arthritis.
Schett G
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
[TBL] [Abstract][Full Text] [Related]
16. Apremilast for the treatment of psoriasis.
Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
[TBL] [Abstract][Full Text] [Related]
17. Apremilast: first global approval.
Poole RM; Ballantyne AD
Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
[TBL] [Abstract][Full Text] [Related]
18. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
19. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Marafini I; Troncone E; Salvatori S; Monteleone G
Pharmacol Res; 2020 May; 155():104757. PubMed ID: 32194176
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
Meier-Schiesser B; Mellett M; Ramirez-Fort MK; Maul JT; Klug A; Winkelbeiner N; Fenini G; Schafer P; Contassot E; French LE
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
